Introducing SmartHeart®, the first fully integrated, portable, 12-lead ECG technology with unlimited 24/7 preliminary reads by SHL clinical staff – for faster, easier and better diagnosis of heart disease.
Join us at booth 1046 and discover how SmartHeart is transforming ECGs, cardiac diagnoses, and 24/7 telehealth support for patients across the country.
Using cutting-edge technology, SmartHeart delivers a high-quality 12-lead ECG with zero professional training or certification required – streamlining heart care for both clinicians and patients. Lightweight and completely portable, SmartHeart is capable of generating quick results in ~30 seconds.
SmartHeart’s fully integrated system eliminates the need for shaving, sticky adhesives or gels. Simply strap the device to the patient’s chest for a quick read on symptoms.
The device delivers an ECG in ~30 seconds with expert interpretations in about 30 minutes. Our HIPAA-compliant data handling process means that patient data is always secure and encrypted.
The in-app guided electrode application ensures a high-quality, accurate ECG is captured every time. When prescribed by a physician, patients can easily perform a full 12-lead ECG on their own.
Using the latest Bluetooth® technology, SmartHeart can pair wirelessly with any smart device to deliver fast and accurate results. Compatible with Apple and Android.
Our network of licensed, credentialed, and board-certified cardiologists are available around-the-clock to provide full ECG interpretations. Unlimited preliminary reads provided by SHL’s global telemedicine center.
Along with unlimited preliminary reviews from our telemedicine service, SmartHeart also offers on-demand, full interpretations from our network of licensed, credentialed, and board-certified cardiologists. These reviews are returned to users within 30 minutes.
We created SmartHeart to support healthcare providers in their goals to extend lifespan, improve patient outcomes and satisfaction – for improved efficiency and total peace of mind.
1. Ben-Assa, Shacham, et al. Is Telemedicine an Answer to Reducing 30-Day Readmission Rates Post–Acute Myocardial Infarction. TELEMEDICINE and e-HEALTH. Sept 2014. Vol. 20.*
2. Roth, Malov, et al. Telemedicine for Post-MI Patients: An Observational Study. Telemedicine and eHealth Vol 15: Jan/Feb 2009.*
*In patients monitored with at home 12-Lead EKG for 1 year following an MI.
ECGs Delivered
We set out to improve health span, reduce mortality, and decrease the financial burden of heart disease. With this in mind, we transformed the gold standard test for screening patients with suspected heart conditions and heart attacks by making it portable, painless and easy to use. For the first time ever, valuable information about your patient’s hearts can be delivered in ~30 seconds and reviewed by a board-certified cardiologist in roughly 30 minutes – for smarter and faster clinical care of heart disease.
Explore the revolutionary 12-lead ECG technology through our webinar, featuring in-depth insights into clinical applications, real-world impact, and an exclusive SmartHeart® demo.
Transform the way you diagnose and manage heart disease with cutting-edge, portable, 12-lead technology and unlimited 24/7 cardiology review. Book a demo today to learn more
The cost of care for patients with acute myocardial infarction continues after patients leave the hospital. At-home solutions offer a cost-effective means to manage cardiovascular disease. Telehealth services facilitated by SmartHeart®, the only FDA-cleared, hospital-grade, remote 12-lead ECG, enables substantial cost savings, while improving outcomes and patient satisfaction.
